<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103021</url>
  </required_header>
  <id_info>
    <org_study_id>Ultrasound PAC</org_study_id>
    <nct_id>NCT04103021</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Port-A-Cath Isertion in Cancer Patients</brief_title>
  <official_title>Effectiveness of Ultrasound Guidance for Port-A-Cath Insertion in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omar Mokhtar Hussein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Port-A-Cath is a totally implanted central venous access system and one of the most
      frequently used systems for administration of chemotherapies in oncological patients .

      The currently used techniques for placement of totally implantable venous access devices
      involve the open insertion by cut down technique, or percutaneous puncture of the central
      vein either by anatomical landmarks or image guided approach by using ultrasound guidance
      which is increasingly being preferred over the traditional anatomical landmark due to its low
      complication rate and high technical success rate; as this technique enables the direct
      visualization of needle entrance and advancement into the target vein
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early complications</measure>
    <time_frame>24 hours</time_frame>
    <description>Early complications associated with Ultrasound guided Port-a-cath insertion periprocedural and within 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late complications</measure>
    <time_frame>Up to 100 months</time_frame>
    <description>complications associated with Ultrasound guided Port-a-cath insertion after 24 hours</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Port-a-cath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided Port-a-cath insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Port-A-Cath</intervention_name>
    <description>Totally implanted central venous access device</description>
    <arm_group_label>Port-a-cath</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cancer patients

          -  Indicated for receiving long term chemotherapy

          -  Accepted coagulation profile.

        Exclusion Criteria:

          -  Severe uncorrectable coagulopathy.

          -  Prior incidence of central vein thrombosis.

          -  Patients with active infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Gebauer B, El-Sheik M, Vogt M, Wagner HJ. Combined ultrasound and fluoroscopy guided port catheter implantation--high success and low complication rate. Eur J Radiol. 2009 Mar;69(3):517-22.</citation>
    <PMID>19340958</PMID>
  </reference>
  <reference>
    <citation>Mudan S, Giakoustidis A, Morrison D, Iosifidou S, Raobaikady R, Neofytou K, Stebbing J. 1000 Port-A-Cath Â® placements by subclavian vein approach: single surgeon experience. World J Surg. 2015 Feb;39(2):328-34. doi: 10.1007/s00268-014-2802-x.</citation>
    <PMID>25245435</PMID>
  </reference>
  <reference>
    <citation>Granziera E, Scarpa M, Ciccarese A, Filip B, Cagol M, Manfredi V, Alfieri R, Celentano C, Cappellato S, Castoro C, Meroni M. Totally implantable venous access devices: retrospective analysis of different insertion techniques and predictors of complications in 796 devices implanted in a single institution. BMC Surg. 2014 May 8;14:27. doi: 10.1186/1471-2482-14-27.</citation>
    <PMID>24886342</PMID>
  </reference>
  <reference>
    <citation>Capalbo E, Peli M, Lovisatti M, Cosentino M, Ticha V, Cariati M, Cornalba G. Placement of port-a-cath through the right internal jugular vein under ultrasound guidance. Radiol Med. 2013 Jun;118(4):608-15. doi: 10.1007/s11547-012-0894-6. Epub 2012 Oct 22.</citation>
    <PMID>23090255</PMID>
  </reference>
  <reference>
    <citation>Funaki B, Szymski GX, Hackworth CA, Rosenblum JD, Burke R, Chang T, Leef JA. Radiologic placement of subcutaneous infusion chest ports for long-term central venous access. AJR Am J Roentgenol. 1997 Nov;169(5):1431-4.</citation>
    <PMID>9353475</PMID>
  </reference>
  <reference>
    <citation>Reeves AR, Seshadri R, Trerotola SO. Recent trends in central venous catheter placement: a comparison of interventional radiology with other specialties. J Vasc Interv Radiol. 2001 Oct;12(10):1211-4.</citation>
    <PMID>11585888</PMID>
  </reference>
  <reference>
    <citation>Miccini M, Cassini D, Gregori M, Gazzanelli S, Cassibba S, Biacchi D. Ultrasound-Guided Placement of Central Venous Port Systems via the Right Internal Jugular Vein: Are Chest X-Ray and/or Fluoroscopy Needed to Confirm the Correct Placement of the Device? World J Surg. 2016 Oct;40(10):2353-8. doi: 10.1007/s00268-016-3574-2.</citation>
    <PMID>27216807</PMID>
  </reference>
  <reference>
    <citation>LaRoy JR, White SB, Jayakrishnan T, Dybul S, Ungerer D, Turaga K, Patel PJ. Cost and Morbidity Analysis of Chest Port Insertion: Interventional Radiology Suite Versus Operating Room. J Am Coll Radiol. 2015 Jun;12(6):563-71. doi: 10.1016/j.jacr.2015.01.012.</citation>
    <PMID>26047398</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Ryu DY, Jung HJ, Lee SS. Evaluation of complications of totally implantable central venous port system insertion. Exp Ther Med. 2019 Mar;17(3):2013-2018. doi: 10.3892/etm.2019.7185. Epub 2019 Jan 18.</citation>
    <PMID>30867691</PMID>
  </reference>
  <reference>
    <citation>Cajozzo M, Palumbo VD, Mannino V, Geraci G, Lo Monte AI, Caronia FP, Fatica F, Romano G, Puzhlyakov V, D'Anna R, Cocchiara G. Ultrasound-guided port-a-cath positioning with the new one-shoot technique: thoracic complications. Clin Ter. 2018 Nov-Dec;169(6):e277-e280. doi: 10.7417/CT.2018.2093.</citation>
    <PMID>30554248</PMID>
  </reference>
  <reference>
    <citation>Zaghal A, Khalife M, Mukherji D, El Majzoub N, Shamseddine A, Hoballah J, Marangoni G, Faraj W. Update on totally implantable venous access devices. Surg Oncol. 2012 Sep;21(3):207-15. doi: 10.1016/j.suronc.2012.02.003. Epub 2012 Mar 17. Review.</citation>
    <PMID>22425356</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 22, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Mokhtar Hussein</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

